- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00861822
Advance Targeted Transfusion in Anemic Cardiac Surgical Patients for Kidney Protection: A Proof of Concept Pilot Study
One of the major complications of heart surgery is kidney injury, which occurs in up to 30% of patients and is associated with poor outcomes including death. We have found that patients whose hemoglobin concentration before surgery is lower than normal (i.e., are anemic) are at particularly high risk for this complication, likely because their hemoglobin concentration drops to very low levels during surgery, which reduces delivery of oxygen to the kidneys, increases blood loss, and necessitates blood transfusions. We and others have shown that these events are individually harmful to the kidneys, and can lead to kidney injury. We believe that we can prevent these events from occurring, and as a result reduce the risk of kidney injury, if we transfuse anemic patients at least 1 day before surgery rather than during surgery.
In anemic patients undergoing cardiac surgery, prophylactic transfusion of red blood cells (RBCs) before surgery will reduce the risk of acute kidney injury (AKI) after surgery by mitigating three inter-related risk factors for AKI.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- Toronto General Hospital, University Health Network
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients undergoing non-emergent aortocoronary bypass (ACB) surgery, or valve surgery, combined ACB and valve, or aortic root repair requiring CPB with a preoperative Hb concentration between 100 and 120 g/L.
Exclusion Criteria:
- Any conditions that may limit the ability of patients to tolerate the intervention:
- Severe aortic or mitral valve stenosis
- History of congestive heart failure within 30 days of surgery or severe ventricular dysfunction (ejection fraction < 30%)
- Severe (> 60%) left main coronary artery stenosis or unstable angina within 30 days of surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: RBC
Advance RBC transfusion' (ART) group
|
Sixty anemic (Hg 100-120 g/L) adult patients undergoing cardiac surgery with CPB will be randomized to the 'advance RBC transfusion' (ART) group or the standard-of-care RBC transfusion' (SRT) group (1:1 ratio). In the ART group, subjects will receive 1-2 units of stored RBCs 1-2 days before surgery to reach a target Hb of 130-140 g/L. Each unit of blood will be transfused over 2 hours under medical supervision, with appropriate monitoring and management of fluid status to ensure patients are not over-hydrate |
Other: Standard Care
Standard-of-care RBC transfusion (SRT) group
|
Sixty anemic (Hg 100-120 g/L) adult patients undergoing cardiac surgery with CPB will be randomized to the 'advance RBC transfusion' (ART) group or the standard-of-care RBC transfusion' (SRT) group (1:1 ratio). In the ART group, subjects will receive 1-2 units of stored RBCs 1-2 days before surgery to reach a target Hb of 130-140 g/L. Each unit of blood will be transfused over 2 hours under medical supervision, with appropriate monitoring and management of fluid status to ensure patients are not over-hydrate |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Effects on perioperative (within 72 hours of termination of CPB) anemia will be measured by: incidence of profound perioperative anemia (Hb < 70 g/L) and by nadir perioperative Hb concentration.
Time Frame: preoperatively, intraoperatively, postoperatively, daily until discharge
|
preoperatively, intraoperatively, postoperatively, daily until discharge
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
(Primary)Effects on periop RBC transfusion rates measured by: incidence and amount of periop RBC transfusions. Effects on periop coagulation measured by: incidence and amount of coagulation product transfusions and incidence of surgical re-exploration.
Time Frame: preoperatively, intraoperatively, postoperatively, daily until discharge
|
preoperatively, intraoperatively, postoperatively, daily until discharge
|
Collaborators and Investigators
Investigators
- Principal Investigator: Keyvan Karkouti, MD, Toronto General Hospital, Toronto, Ontario,Canada
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 08-1083-B
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Injury
-
Instituto Nacional de Cardiologia Ignacio ChavezInstituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranUnknownKidney Injury, Acute | Acute Renal Injury | Acute Kidney Injuries | Kidney Injuries, Acute | Acute Renal InjuriesMexico
-
Mayo ClinicCompletedKidney InjuryUnited States
-
Hospital Medina del CampoCompleted
-
BioPorto DiagnosticsUnknownKidney InjuryUnited States
-
University of PittsburghRenalSense LtdCompletedAcute Kidney Injury | Kidney InjuryUnited States
-
Community Medical Center, Scranton, PACompleted
-
Yonsei UniversityCompletedAcute Kidney Injury(Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery)Korea, Republic of
-
Tel-Aviv Sourasky Medical CenterNot yet recruiting
-
University Hospital, GhentWithdrawn
-
University of NottinghamNot yet recruitingKidney Diseases | Ultrasonography | Kidney Injury, Acute | Perfusion ImagingUnited Kingdom
Clinical Trials on Advanced red blood cell transfusion
-
Bristol-Myers SquibbActive, not recruitingLower-risk Myelodysplastic SyndromesJapan
-
NHS Blood and TransplantUniversity of York; British Medical Research CouncilTerminatedSickle Cell DiseaseUnited Kingdom
-
Sanquin Research & Blood Bank DivisionsNetherlands: Ministry of Health, Welfare and SportsWithdrawnMyelodysplastic SyndromesNetherlands
-
Hvidovre University HospitalIMK FondenUnknown
-
Fundació Institut de Recerca de l'Hospital de la...UnknownCirrhosis | Portal Hypertension | Upper Gastrointestinal BleedingSpain
-
Mayo ClinicDuke University; Blood Systems Research InstituteCompletedBlood Transfusion ComplicationsUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedCancer | SurgeryFrance
-
Australian and New Zealand Intensive Care Research...Not yet recruitingExtracorporeal Membrane Oxygenation Complication | Blood Loss Anemia
-
Juan PascualActive, not recruitingGlucose Transporter Type 1 Deficiency Syndrome | GLUT1DS1United States
-
University Hospital TuebingenGerman Research FoundationCompletedAnemia of PrematurityGermany, Denmark